Tandem Diabetes Care, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 702.80M | 801.22M | 747.72M | 940.20M | 1.01B | 7.9% | |
| Cost of Revenue | (326.58M) | (388.23M) | (380.03M) | (450.63M) | (483.89M) | 7.4% | |
Gross Profit | 376.21M | 412.99M | 367.69M | 489.57M | 530.85M | 8.4% | |
| Operating Expenses | |||||||
| Research & Development | (92.05M) | (170.15M) | (248.42M) | (198.88M) | (174.84M) | -12.1% | |
| Selling, General & Administrative | (261.51M) | (335.68M) | (352.50M) | (389.82M) | (434.13M) | 11.4% | |
| Depreciation & Amortization | (13.85M) | (14.33M) | (15.71M) | (158.00K) | (17.67M) | 11081.0% | |
Operating Income (EBIT) | 22.65M | -92.85M | -233.23M | -99.13M | -78.12M | -21.2% | |
| Non-Operating Items | |||||||
| Interest Income | 674.00K | 6.06M | 22.86M | 17.99M | 9.09M | -49.5% | |
| Interest Expense | (6.04M) | (6.21M) | (9.88M) | (7.42M) | (7.91M) | 6.6% | |
| Other Income/Expenses (Net) | -6.75M | -4.00K | 12.98M | 7.26M | -122.15M | -1783.2% | |
Income Before Tax | 15.90M | -92.85M | -220.25M | -91.87M | -200.27M | 118.0% | |
| Income Tax Expense | (335.00K) | (1.74M) | (2.36M) | (4.16M) | (4.44M) | 6.8% | |
Net Income | 15.57M | -94.59M | -222.61M | -96.03M | -204.71M | 113.2% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $0 | $-1 | $-3 | $-1 | $-3 | 106.8% | |
| Weighted Avg Shares Outstanding | 63.00M | 64.15M | 64.90M | 65.45M | 67.28M | 2.8% | |
| Weighted Avg Shares Outstanding (Diluted) | 64.35M | 64.15M | 64.97M | 65.45M | 67.28M | 2.8% | |
EBITDA | 34.06M | -74.21M | -196.46M | -99.13M | -174.70M | 76.2% |
Explore TNDM
TNDM in the Healthcare
Small Cap